5 Key Takeaways
-
1
The TRUCKEE study evaluated faricimab's efficacy and safety in neovascular age-related macular degeneration over 4.5 years.
-
2
Faricimab showed sustained anatomic improvements and longer treatment intervals in both treatment-naïve and previously treated patients.
-
3
The study involved over 3,600 eyes and 2,900 patients, with nearly 22,000 injections administered.
-
4
Patients switching from aflibercept to faricimab experienced nearly 2-week extension in treatment intervals after 9 injections.
-
5
Faricimab demonstrated a low rate of intraocular inflammation and all reported adverse events resolved with vision returning to baseline.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.